Stepping Beyond the Status Quo in Heart Failure: The Revolutionary Role of SGLT2 Inhibition
This Grand Rounds initiative is targeted to cardiologists, endocrinologists, primary care physicians, pharmacists, nurses, nurse practitioners, and physician assistants. Designed to foster meaningful interprofessional and interdisciplinary collaboration, this accredited activity will explore the evolution of SGLT2 inhibition in the era of cardiovascular outcomes trials (CVOTs), as well as evaluate foundational mechanisms linking type 2 diabetes (T2D) to heart failure (HF). Expert faculty will also examine new and emerging CVOT data for SGLT2 inhibitors, including recent approvals and guideline recommendations, and offer insights into how these agents are shifting the HF treatment paradigm and broadening horizons for both diabetic and nondiabetic patients. To reinforce these teaching points within the context of a collaborative approach, attendees will be engaged in a case-based discussion focused on key characteristics of an effective, integrated approach to HF management.
This activity is presented by Creative Educational Concepts and supported by an independent educational grant from AstraZeneca.
Cardiologists, endocrinologists, primary care physicians, pharmacists, nurses, nurse practitioners, and physician assistants, focused on the integration of new and emerging CVOT data into clinical practice, with an emphasis on collaborative management of heart failure.
At the conclusion of this activity, participants will be able to:
- Explore the evolution of SGLT2 inhibition in the CVOT era and evaluate mechanisms linking T2D and heart failure (HF).
- Appraise new and emerging CVOT data for antihyperglycemic agents and compare outcomes data across the type 2 diabetes (T2D) therapeutic classes.
- Examine recently-reported CVOT data for SGLT2 inhibitors, and discuss ways that these agents are shifting the HF treatment paradigm and broadening horizons for both diabetic and nondiabetic patients.
- Using a case-based format, recognize opportunities for cardiologists to collaborate with endocrinologists, primary care providers, and other members of the healthcare team, and identify key characteristics of an integrated approach to HF management.
Muthiah Vaduganathan, MD, MPH
Harvard Medical School
Brigham and Women’s Hospital
Dr. Vaduganathan is a cardiologist at Brigham and Women’s Hospital and Harvard Medical School (Boston, MA) He is interested in drug development and clinical trials of cardiometabolic therapies. He has authored or co-authored more than 275 peer-reviewed publications.
Dr. Vaduganathan serves on the editorial board of the European Journal of Heart Failure and JACC Heart Failure (Social Media / CME Editor). He serves on the ACCF/AHA Task Force on Performance Measures and is a co-chair on an FDA Think Tank on improving future clinical trials in HF. He participates as a Clinical Endpoints Committee member for ongoing advanced-phase trials in HF / post-MI LV dysfunction.
Jarett Berry, MD- has disclosed that he is a consultant for AstraZeneca and Roche; he also receives grant/research support from Abbott, NIH, and Roche.
Javed Butler, MD, MPH, MBA–has disclosed that he is a consultant for Amgen, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CVRx, G3 Pharmaceutical, Innolife, Janssen, Luitpold, Medtronic, Merck, Novartis, Relypsa, and Vifor.
Muthiah Vaduganathan, MD, MPH–has disclosed that he is a consultant for Amgen, AstraZeneca, Baxter Healthcare, Bayer AG, Boehringer Ingelheim, and Relypsa and receives grant/research support from KL2/Catalyst Medical Research Investigator Training.
Kim Birtcher, MS, PharmD, AACC, FNLA, BCPS-AQ Cardiology, CDE, CLS–has no relevant financial relationships to disclose in relation to the content of this activity.
Debra K. Moser, PhD, RN, FAAN–has no relevant financial relationships to disclose in relation to the content of this activity.
Ambarish Pandey, MD, MSCS–has no relevant financial relationships to disclose in relation to the content of this activity.
Scott Urquhart, PA-C, DFAAPA–has disclosed that he is a consultant for AstraZeneca, Dexcom, Novo Nordisk. and Sanofi. He is a member of the speakers' bureau for AstraZeneca and Novo Nordisk.
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1 hour of Interprofessional Continuing Education (IPCE) credit for learning and change.
CEC designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This application-based activity is approved for 1.0 contact hour (.10 CEUs) of continuing pharmacy education credit (JA0007101-0000-20-008-L01-P).
This activity is designated for 1.0 contact hour.
Physician Assistants (AAPA)
Creative Educational Concepts has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Upon completion of a CE request form, statements of credit for physicians, physician assistants, and nurses will be issued within 30 business days. Pharmacy credit will be reported directly to the National Association of Boards of Pharmacy® NABP® CPE Monitor electronic CE tracking system.
- 1.00 AAPA Category I CME
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 IPCE
- 1.00 Participation